Precigen, Inc.
PRGN-2009
HPV-associated cancers
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews PRGN-2009 for HPV-associated cancers around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“The Company plans to highlight progress across its AdenoVerse portfolio, including an update on PRGN-2009, by end of year.”